▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3709 by analyst upside · 2026-10-16
AUPH
Aurinia Pharmaceuticals Inc.
Healthcare · Market Cap $2B · P/E 7.3x
ANALYST PRICE TARGET
+6.7%
implied upside to consensus target
Current Price $16.73
Consensus Target $17.86
Bull Target $21.0
Bear Target $16.0
Analysts Covering 7
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
5
Hold
2
Sell
0
52-Week Low $11.3
52-Week High $19.25
YTD Return +9.0%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) 7.3x
Forward P/E 15.7x
EPS (TTM) $2.28
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $312M
Profit Margin 100.8%
52-WEEK RANGE
52-Week Low $11.3
52-Week High $19.25
Current Price $16.73
Bear Target $16.0
Bull Target $21.0
● Now $16.73 ● Target $17.86
TRADING DATA
Avg Volume 970K
YTD Return +9.0%
Analyst Count 7
Consensus Buy
Upside to Target +6.7%
Last Updated 2026-10-16

ANALYST SUMMARY

Aurinia Pharmaceuticals Inc. (AUPH) is currently trading at $16.73 with a Wall Street consensus price target of $17.86, implying potential upside of 6.7% over the next 12 months. 7 analysts currently cover AUPH, with a consensus rating of Buy - 71% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $21.0, while the most cautious has a target of $16.0.

AUPH operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 9.0% year-to-date and is currently trading near the upper end of its 52-week range of $11.3 – $19.25.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

MD -5.1%
Pediatrix Medical Group, Inc.
$2B · P/E 13.3x · Hold
HRMY +26.1%
Harmony Biosciences Holdings, Inc.
$2B · P/E 12.3x · Buy
LKFT +1.2%
Lakefront Biotherapeutics NV
$2B · P/E 2.8x · Underperform
INSP -3.0%
Inspire Medical Systems, Inc.
$2B · P/E 15.6x · Hold
PBH +37.8%
Prestige Consumer Healthcare Inc.
$2B · P/E 13.8x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for AUPH, with each firm's 90-day track record across all stocks we track. See full firm rankings →

RBC Capital - Reiterated
Sector Perform → Sector Perform 2026-08-07 Building track record
Leerink Partners ↓ Downgrade
Outperform → Market Perform 2025-12-03 29% win rate (7 calls)
Jefferies ↑ Upgrade
Hold → Buy 2025-11-07 50% win rate (6 calls)
RBC Capital ↓ Downgrade
Outperform → Sector Perform 2025-11-05 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2025-08-01 Building track record
Cantor Fitzgerald reit
Overweight → Overweight 2024-09-16 40% win rate (10 calls)
Cantor Fitzgerald reit
Overweight → Overweight 2024-09-09 40% win rate (10 calls)
HC Wainwright & Co. reit
Buy → Buy 2024-09-06 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
54
out of 100
Coverage depth
16/30
Consensus clarity
24/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →